In January 2019, the European Joint Programme on Rare Diseases (EJP RD) was launched, a major project bringing together research partners, funding agencies, hospitals, foundations and patient organizations from 35 countries. Coordinated by Inserm, its purpose is to create an extremely favorable environment in which research efforts can be coordinated and drug development accelerated. Jointly funded by the European Commission and Member States over five years, the objective is to ensure the program’s sustainability.

QuiTuSais
Wed 20 Feb 2019 – 12:18